Navigation Links
MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting

) of Aloxi in this pediatric population was consistent with that in adults. There were no cardiac safety concerns or serious treatment related adverse events.

Dacogen(R) for Injection

Study of Response to Dacogen in Older Patients Diagnosed with Acute Myelogenous Leukemia (AML)

The impact of Dacogen on the survival of older patients with AML was presented in a poster discussion on Monday, June 4, 2007. A total of 33 patients meeting the WHO definition of AML ( greater than or equal to 20% bone marrow blasts) who had been treated with Dacogen as front-line therapy on either the randomized Phase 3 study in patients with myelodysplastic syndromes, or on two consecutive studies of Dacogen, alone or in combination with valproic acid were evaluated retrospectively. Response to therapy was assessed by the International Working Group criteria. In the 33 patients treated with intravenous Dacogen (100-150 mg/m2/course), an overall response rate ranging from 50-57% was observed across the three clinical trials with complete and partial response rates of 24% and 6%, respectively, and hematologic improvement and marrow complete response rates of 15% and 6%, respectively. The median survival for the Dacogen treated patients was 12.6 months, the median duration of response was 8.8 months, and 1- and 2-year survival rates were 51% and 26%, respectively. Regardless of blast percentage, cytogenetics, or age, responses were observed in all risk groups. Additionally, the survival of the Dacogen treated group compared favorably to that of 330 patients with AML (over 60 years of age) given standard induction therapy containing cytarabine and treated in the same time-period. Non-hematologic adverse events included myocardial infarction, dyspnea, hyperbilirubinemia, dehydration, syncope, headache, and hypokalemia.

Phase 1 Study of Dacogen in Patients with Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)

Interim results of two consecutive phase 1 st
'"/>




Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. MGI Pharma Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
5. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
8. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
9. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
10. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
11. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
Post Your Comments:
(Date:8/20/2014)... , Aug. 20, 2014  Amerigen Pharmaceuticals Ltd. announces ... Ltd., has received Chinese FDA (CFDA) approval and ... Tablets into the China ... and distribution agreement with Sinochem Jiangsu Pharmaceutical Co., ... US FDA approved and China CFDA certified oral ...
(Date:8/20/2014)... , Aug. 20, 2014 Reportlinker.com announces ... in its catalogue: The Market for ... The European, Middle Eastern and African ... devices. As part of its coverage, this study: ... on the EMEA medical device markets and estimates ...
(Date:8/20/2014)... , Aug. 20, 2014 ... research report is available in its catalogue: ... Records http://www.reportlinker.com/p0833392/EMR-2014-The-Market-for-Electronic-Medical-Records.html ... for electronic medical records (EMR) for nearly a ... report of our findings. Our report has become ...
Breaking Medicine Technology:Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA (CFDA) approval and has subsequently launched its generic Mecobalamin 0.5 mg Tablets into the China domestic mark 2The Market for Medical Devices in EMEA 2The Market for Medical Devices in EMEA 3The Market for Medical Devices in EMEA 4The Market for Medical Devices in EMEA 5EMR 2014: The Market for Electronic Medical Records 2EMR 2014: The Market for Electronic Medical Records 3EMR 2014: The Market for Electronic Medical Records 4EMR 2014: The Market for Electronic Medical Records 5EMR 2014: The Market for Electronic Medical Records 6EMR 2014: The Market for Electronic Medical Records 7EMR 2014: The Market for Electronic Medical Records 8
... April 25, 2011 The 2010 Pharmacy Today ... American Pharmacists Association , reveals pharmacists believe that ... was recommended by their pharmacist, 92% of pharmacists walk ... a product selection and the average patient consult takes ...
... Scientific Corporation (NYSE: BSX ) today ... and launch of the ION™ Paclitaxel-Eluting Platinum Chromium ... technology.  The ION Stent System incorporates a unique ... stenting and intended to improve the acute performance ...
Cached Medicine Technology:Pharmacists Offer Guidance on Top Over-The-Counter Medications 2Pharmacists Offer Guidance on Top Over-The-Counter Medications 3Boston Scientific Announces FDA Approval and U.S. Launch of ION™ Platinum Chromium Stent System 2Boston Scientific Announces FDA Approval and U.S. Launch of ION™ Platinum Chromium Stent System 3Boston Scientific Announces FDA Approval and U.S. Launch of ION™ Platinum Chromium Stent System 4Boston Scientific Announces FDA Approval and U.S. Launch of ION™ Platinum Chromium Stent System 5
(Date:8/20/2014)... Angeles, CA (PRWEB) August 20, 2014 ... it is bringing on Wrench Advisors as a ... tasks including international large accounts. , As Wrench ... sales consultants can help your organization plan and ... executives and global distribution channels. Our experience developing ...
(Date:8/20/2014)... 20, 2014 Business owners looking for ways ... a big, lasting impact – should check out the latest ... http://www.PerWickstrom.com . , The new blog post, which is ... Your Business,” highlights that:, , Opportunities for ... and therefore it’s essential to be alert and focused. , ...
(Date:8/20/2014)... TX (PRWEB) August 20, 2014 Texas Medical ... new study. The study will help test the effectiveness of ... suffer from high cholesterol may be eligible to participate in ... much cholesterol in the blood can lead to cardiovascular disease, ... Lowering cholesterol can help reduce the risk of heart disease ...
(Date:8/20/2014)... the 100th anniversary of a revolutionary technique that underpins ... (C&EN) magazine last week released a special edition ... tantalizing glimpse of its future. C&EN is the weekly ... world,s largest scientific society. , The technique got its ... first paper on X-ray diffraction from a crystal in ...
(Date:8/20/2014)... services from the Veterans Health Administration finds general satisfaction, ... studied. , The RAND Corporation study, conducted in 2008 ... disorder were less satisfied than other veterans who received ... were less likely than others to report that staff ... findings, published in the journal Psychiatric Services , ...
Breaking Medicine News(10 mins):Health News:Biocide Systems Announces Partnership with Wrench Advisors 2Health News:Per Wickstrom’s Latest Blog Post Focuses on Small Changes that Can Have a Big Impact on Business 2Health News:Texas Medical Research Associates Announce New Study 2Health News:Survey finds veterans generally satisfied with mental health care 2
... HealthDay Reporter , WEDNESDAY, July 20 (HealthDay News) ... rashes, but the similarities between the two common, distressing ... patients suffering from both ailments (a very rare phenomenon), ... responses that prompt skin flare-ups for both diseases. ...
... Mann HealthDay Reporter , WEDNESDAY, July 20 (HealthDay ... may be heating up. New technology promises to cut costs ... all of your genes and potentially provide a personalized report ... The human genome was first mapped in 2001 and ...
... health, alleviate hunger, raise living standards and empower women ... to play. Jagdev Sharma, a researcher ... Arizona State University,s Biodesign Institute has been investigating the ... villagers in rural Uganda. He reports his findings this ...
... the Breast Health Center at Women & Infants Hospital ... earn a 2011 Breast Cancer Symposium Merit Award from ... Clinical Oncology (ASCO). The award, which recognizes researchers, ... Shannon MacLaughlan, MD, who is also affiliated with The ...
... injuring a muscle through an accident like falling off a ... serious complication. Their muscles start growing bones. ... there was no treatment. But now, research from Northwestern University ... at the University of Pennsylvania shows that a neuropeptide in ...
... American Society for Radiation Oncology (ASTRO) has awarded ... Faculty Career Research Training Award and the Residents/Fellows ... were selected by ASTRO,s Research Evaluation Committee. ... awarded to stimulate interest in radiation research early ...
Cached Medicine News:Health News:Scientists Close in on Origins of Psoriasis, Eczema 2Health News:Scientists Close in on Origins of Psoriasis, Eczema 3Health News:Cheaper DNA Sequencing Coming Closer 2Health News:Cheaper DNA Sequencing Coming Closer 3Health News:A new breed: Highly productive chickens help raise Ugandans from poverty 2Health News:A new breed: Highly productive chickens help raise Ugandans from poverty 3Health News:When injured muscles mistakenly grow bones 2
Ahmed Glaucoma Valve (small size)....
... established. Provides a robust and durable drainage ... on the globe. Pressure Ridge Molteno Implants ... by Tenons tissue, acts as a Pressure ... range of implants allows the surgeon to ...
... a robust and durable drainage system. Preplaced ... globe. Pressure Ridge Molteno Implants have a ... tissue, acts as a Pressure sensitive biological ... implants allows the surgeon to choose the ...
... Baerveldt Glaucoma Implants feature a low ... and reduced complications. The single-quadrant insertion is ... area seton plate to be installed with ... patented fenestrations of the Baerveldt implant were ...
Medicine Products: